Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433146 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL7627282 | 0.86 | CYP1A2 (0.48) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL7624591 | 0.83 | GBA1 (0.47) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL7622461 | 0.82 | GBA1 (0.49) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL7648436 | 0.82 | TSHR (0.62) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL16174483 | 0.82 | CYP1A2 (0.52) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL6001710 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP2A6SLC6A4HTR2AHTR2C | |
| SCHEMBL7622737 | 0.80 | GBA1 (0.51) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL19249099 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 | |
| SCHEMBL19249093 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2A6RAB9ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| WO-2008012546-A2 | AZAPEPTIDES FOR USE IN THERAPY AGAINST INTERSTITIAL CYSTITIS | SOSEI CO. LTD. (JP) | 2008-01-31 | — | — | WO | disclosed |
| EP-1871908-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2008-01-02 | — | — | EP | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| WO-2007020403-A1 | AZAPEPTIDES FOR TREATING HYPERALGESIC PAIN CONDITIONS | SOSEI CO., LTD (GB) | 2007-02-22 | — | — | WO | disclosed |
| EP-1718284-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006105439-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE. AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2006-10-05 | — | — | WO | disclosed |
| EP-0540673-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| US-5288743-A | Lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| US-5250565-A | Must incorporate a metabolically cleavable leaving group; pro-drugs; administering to mammals | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0540673-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1993003719-A1 | ARYLALKYLETHER AND ARYLALKYLTHIOETHER INHIBITORS OF LIPOXYGENASE ENZYME ACTIVITY | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5187192-A | Amide derivatives as antiinflammatory or antiallergy agents | ABBOTT LABORATORIES (US) | 1993-02-16 | — | — | US | disclosed |
| US-5183818-A | Also for inhibiting leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1993-02-02 | — | — | US | disclosed |
| WO-1992001682-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1992-02-06 | — | — | WO | disclosed |
| EP-0416609-A2 | Benzo[b]thiophene-containing lipoxygenase-inhibiting compounds | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | CYP1A2 1450/4885CYP2A6 1747/4885RAB9A 1992/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | CYP1A2 1450/4885CYP2A6 1747/4885RAB9A 1992/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | CYP1A2 1358/4885CYP2A6 2679/4885RAB9A 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.